The question of the treatment of patients with symptoms of the lower urinary tract on the background of benign prostatic hyperplasia with combined erectile dysfunction

Cover Page

Cite item

Full Text

Abstract

The presented literature review deals with the analysis of data on clinical use of a drug from the group of phosphodiesterase enzyme 5 inhibitors in the conservative treatment of patients with a combination of benign prostatic hyperplasia and erectile dysfunction. A similarity of pathophysiological mechanisms which provide and support main manifestations of these two diseases and, as a consequence, complaints presented by patients are showed. The pathophysiological rationale for the use of drugs from the group of phosphodiesterase enzyme 5 inhibitors is given, among which the tadalafil molecule has obvious competitive advantages due to its pharmacological and pharmacokinetic characteristics, in particular the half-life. The data of preclinical and clinical international studies are presented, in which various applications of tadalafil are analyzed: both in the form of monotherapy and in combination with the main drugs used for impaired urination - alpha-1-blocker and 5a-reductase inhibitor. The review provides data on the main studies which design meets the modern requirements of evidence-based medicine. All of these options for the use of this drug for the treatment of patients with impaired urination against a background of prostate adenoma in combination with erectile dysfunction have fairly high efficacy criteria and a favorable safety profile.

About the authors

Anton Iu. Tsukanov

Omsk State Medical University

Email: tsoukanov2000@mail.ru
D. Sci. (Med.), Prof. Omsk, Russia

Sofiia P. Semikina

Omsk State Medical University

Medical Resident Omsk, Russia

References

  1. Gratzke C, Bachmann A, Descazeaud A et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2015; 67: 1099-109.
  2. Gacci M et al. PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH. Curr Bladder Dysfunction Rep 2013; 8: 150-9.
  3. Gacci M et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011; 60: 809-25.
  4. Mondul A.M, Rimm E.B, Giovannucci E et al. A Prospective Study of Lower Urinary Tract Symptoms and Erectile Dysfunction. J Urol 2008; 179 (6): 2321-6.
  5. Laumann E.O, Paik A, Rosen R.C. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281 (6): 537-44.
  6. Blanker M.H, Bohnen A.M, Groeneveld FP et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study. J Am Geriatr Soc 2001; 49 (4): 436-42.
  7. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44 (6): 637-49.
  8. Камалов А.А., Тахирзаде А.М. Современные подходы к консервативному лечению мужчин с сочетанием доброкачественной гиперплазии предстательной железы и эректильной дисфункции. Урология. 2017; 6: 160-3. @@Kamalov A.A., Takhirzade A.M. Sovremennye podkhody k konservativnomu lecheniiu muzhchin s sochetaniem dobrokachestvennoi giperplazii predstatel'noi zhelezy i erektil'noi disfunktsii. Urologiia. 2017; 6: 160-3 (in Russian)
  9. Hammarsten J, Peeker R. Urological aspects of the metabolic syndrome. Nat Rev Urol 2011; 483-94.
  10. Daneshgari F, Liu G, Hanna-Mitchell AT. Path of translational discovery of urological complications of obesity and diabetes. Am J Physiol - Ren Physiol 2017; 312: F887-F896.
  11. Lu T, Lin W-J, Izumi K et al. Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development. Mol Endocrinol 2012; 26: 1707-15.
  12. Sarma A.V, Wei J.T. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med 2012; 367: 248-57.
  13. McVary K.T, Roehrborn C.G, Kaminetsky J.C et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401-7.
  14. Toque H.A, Teixeira C.E, Priviero F.B.M et al. Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets. Br J Pharmacol 2008; 154: 787-96.
  15. Toque H.A, Teixeira C.E, Lorenzetti R et al. Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. Eur J Pharmacol 2008; 591: 189-95.
  16. Toque H.A, Priviero F.B.M, Teixeira C.E et al. Comparative relaxing effects of sildenafil, vardenafil, and tadalafil in human corpus cavernosum: contribution of endogenous nitric oxide release. Urology 2009; 74: 216-21.
  17. Venneri M.A, Giannetta E, Panio G et al. Chronic inhibition of PDE5 limits pro-inflammatory monocyte-macrophage polarization in streptozotocin-induced diabetic mice. PLoS One 2015; 10.
  18. Mokry J, Urbanova A, Medvedova I et al. Effects of tadalafil (PDE5 inhibitor) and roflumilast (PDE4 inhibitor) on airway reactivity and markers of inflammation in ovalbumin-induced airway hyperresponsiveness in guinea pigs. J Physiol Pharmacol. 2017; 68: 721-30.
  19. Islam B.N, Sharman S.K, Hou Y et al. Sildenafil suppresses inflammation-driven colorectal cancer in mice. Cancer Prev Res 2017; 10: 377-88.
  20. El-Naa M.M, Othman M, Younes S. Sildenafil potentiates the antitumor activity of cisplatin by induction of apoptosis and inhibition of proliferation and angiogenesis. Drug Des Devel Ther 2016; 10: 3661.
  21. Dorey G. Are erectile and ejaculatory dysfunction associated with postmicturition dribble? Urol Nurs 2003; 23: 42-5, 48-52.
  22. De Nunzio C, Roehrborn C.G, Andersson K.E, McVary K.T. Erectile dysfunction and lower urinary tract symptoms. Eur Urol Focus 2017; 3: 352-63.
  23. Sexton C.C, Coyne K.S, Kopp Z.S et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int 2009; 103 (Suppl. 3): 12-23.
  24. Irwin D.E, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-14.
  25. Maserejian N.N, Kupelian V, McVary K.T et al. Prevalence of postmicturition symptoms in association with lower urinary tract symptoms and health-related quality of life in men and women. BJU Int 2011; 108: 1452-8.
  26. Poyhonen A, Auvinen A, Koskimaki J et al. Prevalence and bother of postmicturition dribble in finnish men aged 30-80 years: tampere ageing male urologic study (TAMUS). Scand J Urol Nephrol 2012; 46: 418-23.
  27. Coyne KS, Sexton C.C, Thompson C.L et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the epidemiology of LUTS (EpiLUTS) study. BJU Int 2009; 104: 352-60.
  28. Agarwal A, Eryuzlu L.N, Cartwright R et al. What is the most bothersome lower urinary tract symptom? Individual- and populationlevel perspectives for both men and women. Eur Urol 2014; 65: 1211-7.
  29. Poyhonen A, Auvinen A, Hakkinen J.T et al. Population-level and individual-level bother of lower urinary tract symptoms among 30- to 80-year-old men. Urology 2016; 95: 164-70.
  30. Yang D.Y, Ko K, Lee S.H et al. Postmicturition dribble is associated with erectile dysfunction in middle-aged and older men with lower urinary tract symptoms. World J Mens Health 2018; 36: 263-70.
  31. Macfarlane G.J, Botto H, Sagnier P.P et al. The relationship between sexual life and urinary condition in the French community. J Clin Epidemiol 1996; 49: 1171-6.
  32. Frankel S.J, Donovan J.L, Peters T.I et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol 1998; 51: 677-85.
  33. Shafik A, Shafik I.A, El Sibai O, Shafik A.A. Study of the response of the penile corporal tissue and cavernosus muscles to micturition. BMC Urol 2008; 8: 4.
  34. Ferrer J.E, Velez J.D, Herrera A.M. Age-related morphological changes in smooth muscle and collagen content in human corpus cavernosum. J Sex Med 2010; 7: 2723-8.
  35. Costa C, Vendeira P. Does erectile tissue angioarchitecture modify with aging? An immunohistological and morphometric approach. J Sex Med 2008; 5: 833-40.
  36. Giuliano F, Uckert S, Maggi M et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol 2013; 63: 506-16.
  37. Урология. Российские клинические рекомендации. Под ред. Ю.Г.Аляева, П.В.Глыбочко, Д.Ю.Пушкаря. М., 2017. @@Urology. Russian clinical guidelines. Ed.: Yu.G.Alaev, P.V.Glybochko, D.Y.Pushkar. Moscow, 2017 (in Russian)
  38. Говоров А.В., Касян Г.Р., Васильев А.О., Пушкарь Д.Ю. Тадалафил в лечении симптомов со стороны нижних мочевых путей: обзор литературы и существующей клинической практики в России. Consilium Medicum. 2014; 16 (7): 33-41. @@Govorov A.V., Kasyan G.R., Vasil’ev A.O., Pushkar D.Yu. Adalafil in the treatment of symptoms from the lower urinary tract: a review of literature and existing clinical practice in Russia. Consilium Medicum. 2014; 16 (7): 33-41 (in Russian).]
  39. Камалов А.А., Охоботов Д.А., Тахирзаде А.М. и др. Комбинированная терапия больных с симптомами нижних мочевых путей и эректильной дисфункцией. Естественные и технические науки. 2013; 1: 105-13. @@Kamalov A.A., Okhobotov D.A., Takhirzade A.M. et al. Kombinirovannaia terapiia bol'nykh s simptomami nizhnikh mochevykh putei i erektil'noi disfunktsiei. Estestvennye i tekhnicheskie nauki. 2013; 1: 105-13 (in Russian).]
  40. Gacci M, Andersson K.E, Chapple C et al. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Eur Urol 2016; 70 (1): 124-33.
  41. Brock G.B, McVary K.T, Roehrborn C.G et al. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies. J Urol 2014; 191 (2): 405-11.
  42. Gacci M.I, Corona G, Salvi M et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with a-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012; 61 (5): 994-1003.
  43. Giuliano F.I, Oelke M, Jungwirth A et al. Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study. J Sex Med 2013; 10 (3): 857-65.
  44. European association of urology. Guidelines. Management of Non-neurogenic Male LUTS. S. Gravas (Chair), J.N. Cornu, M. Gacci, C. Gratzke, T.R.W. Herrmann, C. Mamoulakis, M. Rieken, M.J. Speakman, K.A.O. Tikkinen, 2019.
  45. Mujoo K, Sharin V.G, Martin E et al. Role of soluble guanylyl cyclase-cyclic GMP signaling in tumor cell proliferation. Nitric Oxide - Biol Chem 2010; 22: 43-50.
  46. Sotolongo A, Mónica F.Z, Kots A et al. Epigenetic regulation of soluble guanylate cyclase (sGC) b1 in breast cancer cells. FASEB J 2016; 30: 3171-80.
  47. Lin J.E, Li P, Snook A.E et al. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling. Gastroenterology 2010; 138: 241-54.
  48. Rappaport J.A, Waldman S.A. The guanylate cyclase C - cGMP signaling axis opposes intestinal epithelial injury and neoplasia. Front Oncol 2018; 8: 299.
  49. Liu N, Mei L, Fan X et al. Phosphodiesterase 5/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway. Cancer Lett 2016; 378: 38-50.
  50. Egerdie R.B, Auerbach S, Roehrborn C.G et al. Tadalafil 2.5 or 5 mg administered once daily for
  51. weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, doubleblind study. J Sex Med 2012; 9: 271-81.
  52. Волков А.А., М.И. Петричко, Н.В. Будник. Ежедневный прием ингибиторов фосфодиэстеразы 5-го типа - коррекция эректильной дисфункции и симптомов нижних мочевых путей у больных аденомой предстательной железы. Урология. 2014; 4: 64-8. @@Volkov A.A., Petrichko M.I., Budnik N.V. Daily use of type 5 phosphodiesterase inhibitors - correction of erectile dysfunction and lower urinary tract symptoms in patients with prostate adenoma. Urologija. 2014; 4: 64-8 (In Russian).]
  53. McVary K.T, Roehrborn C.G, Kaminetsky J.C et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401-7.
  54. Bechara A, Romano S, Casabé A et al. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008; 5: 2170-8.
  55. Porst H, McVary K.T, Montorsi F et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol 2009; 56: 727-36.
  56. Roehrborn C.G, McVary K.T, Elion-Mboussa A et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008; 180: 1228-34.

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies